Literature DB >> 1322894

Lipoxin recognition sites. Specific binding of labeled lipoxin A4 with human neutrophils.

S Fiore1, S W Ryeom, P F Weller, C N Serhan.   

Abstract

Lipoxin A4 stimulates rapid lipid remodeling and a pertussis toxin-sensitive release of arachidonic acid in polymorphonuclear leukocytes (PMN) (Nigam, S., Fiore, S., Luscinskas, F.W., and Serhan, C.N. (1990) J. Cell. Physiol. 143, 512-523) and has been shown to inhibit leukocyte responses in several systems. To examine the basis underlying these actions, we have prepared [11,12-3H]lipoxin A4 (LXA4) and characterized its interactions with human PMN. Time course studies (0-90 min) with intact PMN demonstrated cell association of 3H label which was specific and reversible. PMN bound [3H]LXA4 with a Kd of 0.5 +/- 0.3 nM, representing approximately 1,830 sites/PMN, and the Hill plot value of 1.9 suggests cooperative binding. [3H]LXA4 binding was stereoselective since neither leukotriene B4 (LTB4), lipoxin B4 (LXB4), (6S)-LXA4, 11-trans-LXA4, nor SKF 104353 competed for [3H]LXA4-specific binding while LTD4 and LTC4 partially competed. Subcellular fractionation revealed that specific binding with [3H]LXA4 was associated with membrane (42.1%)-, granule (34.5%)-, and nuclear (23.3%)-enriched fractions, a distribution distinct from that of [14,15-3H] LTB4 binding. [11,12-3H]LXA4-specific binding was modulated by guanosine analogs, suggesting the involvement of G proteins. A fluorescent LXA4 derivative (methyl-7-methoxycoumarin-LXA4) competed with [3H]LXA4 binding to intact PMN and showed specific and reversible binding as monitored by flow cytometric analysis. These results indicate that PMN possess specific recognition sites for LXA4 which may mediate its actions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1322894

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

Review 1.  12-lipoxygenase: a potential target for novel anti-platelet therapeutics.

Authors:  Jennifer Yeung; Michael Holinstat
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2011-07-01

Review 2.  Novel anti-inflammatory--pro-resolving mediators and their receptors.

Authors:  Charles N Serhan; Sriram Krishnamoorthy; Antonio Recchiuti; Nan Chiang
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

3.  Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues.

Authors:  T Takano; C B Clish; K Gronert; N Petasis; C N Serhan
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

Review 4.  Control of myeloid cell trafficking in resolution.

Authors:  Lucy V Norling; Mauro Perretti
Journal:  J Innate Immun       Date:  2013-04-30       Impact factor: 7.349

Review 5.  Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers.

Authors:  Charles N Serhan; Makoto Arita; Song Hong; Katherine Gotlinger
Journal:  Lipids       Date:  2004-11       Impact factor: 1.880

Review 6.  A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution.

Authors:  Charles N Serhan
Journal:  Histochem Cell Biol       Date:  2004-08-21       Impact factor: 4.304

Review 7.  Lipoxins: resolutionary road.

Authors:  Paola Maderna; Catherine Godson
Journal:  Br J Pharmacol       Date:  2009-09-28       Impact factor: 8.739

8.  Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGFβR1.

Authors:  Eoin P Brennan; Karen A Nolan; Emma Börgeson; Oisín S Gough; Caitríona M McEvoy; Neil G Docherty; Debra F Higgins; Madeline Murphy; Denise M Sadlier; Syed Tasadaque Ali-Shah; Patrick J Guiry; David A Savage; Alexander P Maxwell; Finian Martin; Catherine Godson
Journal:  J Am Soc Nephrol       Date:  2013-03-21       Impact factor: 10.121

9.  Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers.

Authors:  S P Colgan; C N Serhan; C A Parkos; C Delp-Archer; J L Madara
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

Review 10.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.